IsoRay (ISR) Announces Quarterly Earnings Results, Meets Estimates

IsoRay (NYSEAMERICAN:ISR) issued its earnings results on Thursday. The healthcare company reported ($0.02) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02), reports. The company had revenue of $1.56 million for the quarter, compared to the consensus estimate of $1.73 million.

NYSEAMERICAN ISR traded down $0.05 during trading hours on Friday, reaching $0.39. 806,773 shares of the company were exchanged, compared to its average volume of 628,840. IsoRay has a 1 year low of $0.36 and a 1 year high of $1.22.

Several brokerages recently issued reports on ISR. Maxim Group lowered shares of IsoRay from a “buy” rating to a “hold” rating in a research note on Friday. Zacks Investment Research raised shares of IsoRay from a “sell” rating to a “hold” rating in a research note on Friday. Finally, HC Wainwright set a $1.00 target price on shares of IsoRay and gave the stock a “hold” rating in a research note on Wednesday, September 26th.

COPYRIGHT VIOLATION NOTICE: “IsoRay (ISR) Announces Quarterly Earnings Results, Meets Estimates” was first published by WKRB News and is owned by of WKRB News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at

IsoRay Company Profile

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Read More: Balance Sheet

Earnings History for IsoRay (NYSEAMERICAN:ISR)

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.

Leave a Reply